Equities analysts expect that Avrobio Inc (NASDAQ:AVRO) will report earnings of ($0.58) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Avrobio’s earnings, with estimates ranging from ($0.69) to ($0.47). The business is scheduled to announce its next earnings results on Tuesday, February 12th.
According to Zacks, analysts expect that Avrobio will report full year earnings of ($3.12) per share for the current year, with EPS estimates ranging from ($4.57) to ($1.82). For the next fiscal year, analysts forecast that the company will report earnings of ($2.14) per share, with EPS estimates ranging from ($2.93) to ($1.29). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Avrobio.
Avrobio (NASDAQ:AVRO) last released its quarterly earnings data on Tuesday, November 13th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.42.
AVRO stock traded up $0.67 during midday trading on Friday, reaching $24.75. 16,241 shares of the company were exchanged, compared to its average volume of 86,002. Avrobio has a 1-year low of $20.30 and a 1-year high of $53.70.
Several institutional investors have recently made changes to their positions in AVRO. American International Group Inc. acquired a new position in shares of Avrobio in the 3rd quarter valued at $210,000. TD Asset Management Inc. acquired a new position in Avrobio in the 2nd quarter valued at $217,000. Rhumbline Advisers acquired a new position in Avrobio in the 3rd quarter valued at $235,000. BlackRock Inc. acquired a new position in Avrobio in the 2nd quarter valued at $248,000. Finally, Northern Trust Corp acquired a new position in Avrobio in the 2nd quarter valued at $255,000. 67.57% of the stock is currently owned by institutional investors and hedge funds.
Avrobio Company Profile
AVROBIO, Inc, a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease.
Read More: What is the float in trading stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.